Literature DB >> 3778483

CB 1954 (2,4-dinitro-5-aziridinyl benzamide) becomes a DNA interstrand crosslinking agent in Walker tumour cells.

J J Roberts, F Friedlos, R J Knox.   

Abstract

Walker tumour cells were shown to be uniquely sensitive to CB 1954 when compared with other cells in vitro. CB 1954 forms DNA-DNA interstrand crosslinks in a time-dependent manner in Walker tumour but not Chinese hamster cells. The absence of interstrand crosslinks in hamster cells was not due to a lack of uptake of drug but rather to a failure to convert (probably by bioreduction) CB 1954 to the required reactive difunctional intermediate.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3778483     DOI: 10.1016/0006-291x(86)90744-8

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  Cone degeneration following rod ablation in a reversible model of retinal degeneration.

Authors:  Rene Y Choi; Gustav A Engbretson; Eduardo C Solessio; Georgette A Jones; Adam Coughlin; Ilija Aleksic; Michael E Zuber
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-01-21       Impact factor: 4.799

2.  Prodrugs in Cancer Chemotherapy.

Authors:  Richard J Knox; Tom A Connors
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

3.  A novel model of retinal ablation demonstrates that the extent of rod cell death regulates the origin of the regenerated zebrafish rod photoreceptors.

Authors:  Jacob E Montgomery; Michael J Parsons; David R Hyde
Journal:  J Comp Neurol       Date:  2010-03-15       Impact factor: 3.215

Review 4.  The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT).

Authors:  R J Knox; F Friedlos; M P Boland
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

5.  Pineal photoreceptor cells are required for maintaining the circadian rhythms of behavioral visual sensitivity in zebrafish.

Authors:  Xinle Li; Jake Montgomery; Wesley Cheng; Jung Hyun Noh; David R Hyde; Lei Li
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

6.  Antibody directed enzymes revive anti-cancer prodrugs concept.

Authors:  K D Bagshawe
Journal:  Br J Cancer       Date:  1987-11       Impact factor: 7.640

7.  Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK.

Authors:  D R Newell; K M Searle; N B Westwood; S S Burtles
Journal:  Br J Cancer       Date:  2003-08-04       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.